Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABSORB 2: Oral antibiotic absorption in short bowel syndrome
2019-002587-28Phase 4Completed
- Sponsor
- Radboudumc
- Start
- Aug 2019
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ciprofloxacin, clindamycin, flucloxacillin and fluconazole in short bowel syndrome (SBS) and catheter infection, sponsored by Radboudumc. Primary endpoints: Relative oral bioavailability of flucloxacillin, Relative oral bioavailability of clindamycin and 2 more. Started Aug 2019; status: completed.
02
Drugs
ciprofloxacinclindamycinflucloxacillinfluconazole
03
Conditions
short bowel syndrome (SBS)catheter infection
Beyond the preview
Go deeper on 2019-002587-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002587-28.